CER-522 (Peptide Mimetic)
CER-522 is an HDL mimetic based on a peptide analogue of ApoA-I. This program is being evaluated for the treatment of aortic valve stenosis (AVS).
AVS is the most common valvular disorder in developed countries. The prevalence of AVS increases with age and is present in 2-4% of adults over the age of 65 and it is a gradually progressive disorder and aortic valve replacement remains the only definitive treatment.
AVS is believed to be an active disease process with similarities to atherosclerosis; histopatholgic studies of calcific aortic valves have demonstrated atheroma-like plaques.
Although LDL-lowering therapies have failed to show a benefit in AVS patients, there is hope that HDL mimetics may have therapeutic value.
CER-522 is currently under Phase 1 clinical development.